Quidel (Nasdaq:QDEL) announced today that it completed its $6 billion acquisition of Ortho Clinical Diagnostics (Nasdaq:OCDX). In December 2021, San Diego-based Quidel and Ortho Clinical Diagnostics came to an agreement under which the former would acquire the latter for $24.68 per share of common stock, using a combination of cash and newly issued shares in […]
Ortho Clinical Diagnostics
Quidel to acquire Ortho Clinical Diagnostics for $6B
Quidel (NSDQ:QDEL) announced today that it acquired Ortho Clinical Diagnostics (NSDQ:OCDX) for approximately $6 billion. Under a definitive agreement,Quidel will acquire Ortho for $24.68 per share of common stock, using a combination of cash and newly issued shares in the combined company, representing a 25% premium on Ortho’s closing price on Dec. 22, 2021, and […]
Ortho Clinical Diagnostics lands CE mark for high-volume COVID-19 test
Ortho Clinical Diagnostics (NSDQ:OCDX) announced that it received a CE mark for its Vitros SARS-CoV-2 antigen test for COVID-19. European approval follows the Vitros test’s initial launch in October 2020. The CE mark allows for more convenient sample collection and expanded viral transport media, according to a news release. Personnel at hospitals, labs and other […]
Ortho Clinical Diagnostics wins nearly $53.7M BARDA contract for COVID-19 tests
Ortho Clinical Diagnostics (NSDQ:OCDX) announced that it received a $53.7 million government contract for its COVID-19 tests. Raritan, N.J.–based Ortho Clinical Diagnostics was awarded an undefinitized contract set to lead to a $53.7 million contract from the Biomedical Advanced Research and Development Authority (BARDA) as a continuation of the partnership between the two entities, according […]
Ortho Clinical Diagnostics COVID-19 antibody tests wins CE mark
Ortho Clinical Diagnostics (NSDQ:OCDX) announced today that its new Vitros SARS-CoV-2 antibody assays received CE Mark approval. Raritan, N.J.-based Ortho Clinical Diagnostics’ Vitros anti-SARS-CoV-2 total 2 antibody assay and the Vitros anti-SARS-CoV-2 IgG 2 antibody assay both received European approval for the qualitative and semi-quantitative detection of COVID-19 antibodies, according to a news release. Both […]
BARDA awards $12.9M to Ortho Clinical for coronavirus antigen test
Ortho Clinical Diagnostics announced that it received a nearly $12.9 million award from BARDA to support the development of its COVID-19 antigen test. Raritan, N.J.-based Ortho Clinical Diagnostics and the Biomedical Advanced Research and Development Authority (BARDA) are working together under a new contract as part of the government’s ongoing COVID-19 medical countermeasure development efforts, according […]
AdvaMed unveils COVID-19 diagnostic supply registry
AdvaMed announced today that it created a comprehensive national COVID-19 diagnostic supply registry to aid state and federal pandemic responses. According to a news release, AdvaMed is launching the registry in partnership with 13 commercial diagnostics manufacturers: Abbott (NYSE:ABT), Becton Dickinson (NYSE:BDX), bioMérieux, Bio-Rad Laboratories (NYSE:BIO), Beckman Coulter, Cepheid, Hologic (NSDQ:HOLX), Ortho Clinical Diagnostics, Qiagen (NYSE:QGEN), Roche Diagnostics, Sekisui Diagnostics, […]
Are coronavirus antibody tests all they’re cracked up to be?
With pressure mounting to get Americans back to work, the new focus is on tests that purport to indicate antibodies to the SARS-CoV-2. These serological tests are supposed measure the amount of antibodies or proteins present in the blood when the body is responding to a specific infection, like COVID-19. Many companies in China have […]
Insulin assay from Ortho Clinical Diagnostics nabs FDA nod
Ortho Clinical Diagnostics said yesterday that its Vitros insulin assay and calibrators won 510(k) clearance from the FDA. The Raritan, N.J.-based company reported that the diabetes and pre-diabetes diagnostic test is slated to be commercially available in the 3rd quarter of this year. Get the full story at our sister site, Drug Delivery Business News.
7 medtech stories we missed this week: March 24, 2017
From companies receiving CE marking to other companies adjusting their distribution deals, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Viveve Medical closes public offering Viveve Medical announced that it closed its underwritten public offering of 8,625,00 shares of its common stock, according to a March 22 […]